BEAM – Beam Therapeutics Inc.
Beam Therapeutics Inc.BEAM
$15.10Name : Beam Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,507,584,000.00
EPSttm : -4.58
Beam Therapeutics Inc.
$15.10
8.26%$1.36Float Short %
13.82
Margin Of Safety %
Put/Call OI Ratio
0.51
EPS Next Q Diff
-0.06
EPS Last/This Y
-0.08
EPS This/Next Y
0.05
Price
16.42
Target Price
48.06
Analyst Recom
1.39
Performance Q
-33.63
Relative Volume
1.9
Beta
2.35
Ticker: BEAM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | BEAM | 26.11 | 0.62 | 0.50 | 14569 |
| 2025-03-06 | BEAM | 27.26 | 0.62 | 0.09 | 15316 |
| 2025-03-07 | BEAM | 28.46 | 0.55 | 2.12 | 16404 |
| 2025-03-10 | BEAM | 25.68 | 0.34 | 1.01 | 15466 |
| 2025-03-11 | BEAM | 26.42 | 0.39 | 0.41 | 16404 |
| 2025-03-12 | BEAM | 27.43 | 0.39 | 0.31 | 16477 |
| 2025-03-13 | BEAM | 25.06 | 0.39 | 0.59 | 16515 |
| 2025-03-14 | BEAM | 24.22 | 0.39 | 0.57 | 16918 |
| 2025-03-17 | BEAM | 24.5 | 0.40 | 0.36 | 17395 |
| 2025-03-18 | BEAM | 22.56 | 0.39 | 1.49 | 17610 |
| 2025-03-19 | BEAM | 23.74 | 0.42 | 1.64 | 18093 |
| 2025-03-20 | BEAM | 22.85 | 0.42 | 2.18 | 18056 |
| 2025-03-21 | BEAM | 23.11 | 0.39 | 0.15 | 17803 |
| 2025-03-24 | BEAM | 24.03 | 0.43 | 0.21 | 11105 |
| 2025-03-25 | BEAM | 23.22 | 0.40 | 0.75 | 11840 |
| 2025-03-26 | BEAM | 22.07 | 0.43 | 0.63 | 12300 |
| 2025-03-27 | BEAM | 22.17 | 0.44 | 0.35 | 12707 |
| 2025-03-28 | BEAM | 22.19 | 0.45 | 0.37 | 12891 |
| 2025-03-31 | BEAM | 19.52 | 0.45 | 0.44 | 13567 |
| 2025-04-01 | BEAM | 17.63 | 0.48 | 1.08 | 14181 |
| 2025-04-02 | BEAM | 18.49 | 0.53 | 0.10 | 15320 |
| 2025-04-03 | BEAM | 16.46 | 0.51 | 0.78 | 16215 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | BEAM | 26.12 | -0.6 | - | -4.80 |
| 2025-03-06 | BEAM | 27.27 | -0.6 | - | -4.84 |
| 2025-03-07 | BEAM | 28.47 | -0.6 | - | -4.84 |
| 2025-03-10 | BEAM | 25.69 | -0.6 | - | -4.84 |
| 2025-03-11 | BEAM | 26.42 | -0.6 | - | -4.84 |
| 2025-03-12 | BEAM | 27.43 | 2.4 | - | -4.70 |
| 2025-03-13 | BEAM | 25.06 | 2.4 | - | -4.70 |
| 2025-03-14 | BEAM | 24.23 | 2.8 | - | -4.68 |
| 2025-03-17 | BEAM | 24.52 | 3.4 | - | -4.65 |
| 2025-03-18 | BEAM | 22.56 | 3.4 | - | -4.65 |
| 2025-03-19 | BEAM | 23.64 | 3.4 | - | -4.65 |
| 2025-03-20 | BEAM | 22.87 | 3.2 | - | -4.66 |
| 2025-03-21 | BEAM | 23.31 | 3.2 | - | -4.66 |
| 2025-03-24 | BEAM | 24.01 | 3.2 | - | -4.66 |
| 2025-03-25 | BEAM | 23.22 | 3.2 | - | -4.66 |
| 2025-03-26 | BEAM | 21.91 | 3.2 | - | -4.66 |
| 2025-03-27 | BEAM | 22.17 | 3.2 | - | -4.66 |
| 2025-03-28 | BEAM | 22.21 | 3.2 | - | -4.66 |
| 2025-03-31 | BEAM | 19.51 | 3.2 | - | -4.66 |
| 2025-04-01 | BEAM | 17.64 | 3.2 | - | -4.66 |
| 2025-04-02 | BEAM | 18.48 | 3.2 | - | -4.66 |
| 2025-04-03 | BEAM | 16.42 | 3.2 | - | -4.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | BEAM | -2.07 | -2.78 | 12.54 |
| 2025-03-06 | BEAM | -2.07 | -2.78 | 12.54 |
| 2025-03-07 | BEAM | -2.07 | -2.78 | 12.54 |
| 2025-03-10 | BEAM | -2.07 | -2.77 | 12.54 |
| 2025-03-11 | BEAM | -2.07 | -2.77 | 12.54 |
| 2025-03-12 | BEAM | -2.07 | -2.77 | 13.56 |
| 2025-03-13 | BEAM | -1.76 | -2.77 | 13.54 |
| 2025-03-14 | BEAM | -1.76 | -2.77 | 11.35 |
| 2025-03-17 | BEAM | -1.76 | -2.33 | 11.35 |
| 2025-03-18 | BEAM | -1.76 | -2.33 | 11.35 |
| 2025-03-19 | BEAM | -1.76 | -2.33 | 11.35 |
| 2025-03-20 | BEAM | -1.76 | -2.33 | 11.35 |
| 2025-03-21 | BEAM | -1.76 | -2.33 | 11.35 |
| 2025-03-24 | BEAM | -1.76 | -2.32 | 11.35 |
| 2025-03-25 | BEAM | -1.76 | -2.32 | 11.35 |
| 2025-03-26 | BEAM | -1.76 | -2.32 | 13.82 |
| 2025-03-27 | BEAM | -1.76 | -2.32 | 13.82 |
| 2025-03-28 | BEAM | -1.76 | -2.32 | 13.82 |
| 2025-03-31 | BEAM | -1.76 | -2.33 | 13.82 |
| 2025-04-01 | BEAM | -1.76 | -2.33 | 13.82 |
| 2025-04-02 | BEAM | -1.76 | -2.33 | 13.82 |
| 2025-04-03 | BEAM | -1.26 | -2.33 | 13.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.09
Avg. EPS Est. Current Quarter
-1.17
Avg. EPS Est. Next Quarter
-1.15
Insider Transactions
-1.26
Institutional Transactions
-2.33
Beta
2.35
Average Sales Estimate Current Quarter
14
Average Sales Estimate Next Quarter
15
Fair Value
Quality Score
19
Growth Score
38
Sentiment Score
28
Actual DrawDown %
88.1
Max Drawdown 5-Year %
-86.8
Target Price
48.06
P/E
Forward P/E
PEG
P/S
25.87
P/B
1.88
P/Free Cash Flow
EPS
-4.58
Average EPS Est. Cur. Y
-4.66
EPS Next Y. (Est.)
-4.62
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-593.13
Relative Volume
1.9
Return on Equity vs Sector %
-71.2
Return on Equity vs Industry %
-58.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.1
EBIT Estimation
Beam Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 483
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
stock quote shares BEAM – Beam Therapeutics Inc. Stock Price stock today
news today BEAM – Beam Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BEAM – Beam Therapeutics Inc. yahoo finance google finance
stock history BEAM – Beam Therapeutics Inc. invest stock market
stock prices BEAM premarket after hours
ticker BEAM fair value insiders trading